Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Peter Clark, MA, MD, FRCP: A Payer Perspective

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

David A. Hyman, MD, JD, on Inclusive Shared Savings

Oct

Today In Oncology

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Related Videos

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Peter Clark, MA, MD, FRCP: A Payer Perspective

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

David A. Hyman, MD, JD, on Inclusive Shared Savings

Depression Increases Cancer-Specific Mortality Risks in Common Cancers

Real-World Data Indicate Lower Adherence Rates for Breast Cancer Endocrine Therapy When Radiation Therapy Is Omitted

SYMPRO-Lung: Could Weekly PRO Symptom Monitoring Improve Survival Outcomes in Any-Stage Lung Cancer?

Mindfulness and Tai Chi May Improve Symptoms After Cancer Treatment

Cleveland Clinic to Host Second Annual AI Summit for Health-Care Professionals